Nona Biosciences is at the forefront of biotechnological innovation, offering comprehensive solutions in therapeutic antibody research and development. With a commitment to empowering global biotherapeutic innovation, nona Biosciences leverages its proprietary Harbour Mice® platforms and the Beacon® single B cell screening platform to generate fully human monoclonal antibodies. This cutting-edge approach not only accelerates the discovery process but also ensures the development of highly effective and safe therapeutics.
The company’s dedication to advancing drug development is evident in its versatile Harbour Mice® platform, which produces antibodies in both H2L2 and heavy chain-only (HCAb) formats. These platforms are instrumental in generating bi- and multi-specific antibodies, CAR-T cells, and antibody-drug conjugates (ADCs), showcasing Nona Biosciences’ role in pioneering next-generation therapeutic modalities.
Nona Biosciences’ integrated services span from antigen preparation and animal immunization to antibody lead generation, engineering, and pharmacological evaluation. This comprehensive approach ensures a seamless transition from idea to investigational new drug (IND) application, supporting partners ranging from academic institutions to major biopharmaceutical companies.
The company’s mission to provide a total antibody discovery and development solution underscores its commitment to driving the invention of transformative drugs. Through diversified partnership strategies and a flexible business model, Nona Biosciences is not just a service provider but a collaborator in the quest for groundbreaking biopharmaceutical advancements.
In conclusion, Nona Biosciences exemplifies the power of innovation in the biotech industry, offering a beacon of hope for the development of next-generation therapeutics. With its advanced platforms and comprehensive services, Nona Biosciences is poised to continue leading the way in biotherapeutic innovation.
